Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.
Administration, Intravenous
Aged
Allografts
/ immunology
B-Lymphocytes
Female
Follow-Up Studies
Glomerular Filtration Rate
Graft Rejection
/ immunology
Humans
Immunosuppression Therapy
/ adverse effects
Kidney
/ immunology
Kidney Failure, Chronic
/ surgery
Kidney Transplantation
/ adverse effects
Lymphocyte Count
Male
Mesenchymal Stem Cell Transplantation
/ adverse effects
Middle Aged
Prospective Studies
T-Lymphocytes, Regulatory
/ immunology
Transplantation, Homologous
/ adverse effects
Treatment Outcome
cell therapy
kidney transplantation
mesenchymal stromal cells
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
07
03
2018
revised:
25
07
2018
accepted:
23
08
2018
pubmed:
12
12
2018
medline:
15
2
2020
entrez:
12
12
2018
Statut:
ppublish
Résumé
Mesenchymal stromal cells (MSCs) exhibit anti-inflammatory and immune-regulatory properties, and preclinical studies suggest a potential benefit in solid organ transplantation. We report on the 1-year follow-up of an open-label phase I-II trial of a single infusion of third-party MSC post-kidney transplantation, in addition to standard immunosuppression. Ten kidney transplant recipients from deceased donors received third-party bone marrow MSCs (∼2 × 10
Identifiants
pubmed: 30528263
pii: S0085-2538(18)30712-9
doi: 10.1016/j.kint.2018.08.046
pii:
doi:
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-707Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.